These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35621089)

  • 1. Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice.
    Rola P; Włodarczak A; Łanocha M; Barycki M; Szudrowicz M; Kulczycki JJ; Jaroszewska-Pozorska J; Gosiewska A; Woźnica K; Lesiak M; Doroszko A
    Cardiol J; 2022 May; 30(6):870-80. PubMed ID: 35621089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions.
    Włodarczak A; Rola P; Włodarczak S; Szudrowicz M; Giniewicz K; Łanocha M; Jaroszewska-Pozorska J; Barycki M; Furtan Ł; Kędzierska M; Włodarczak P; Doroszko A; Lesiak M
    J Pers Med; 2024 May; 14(5):. PubMed ID: 38793122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 1-Year Safety and Efficacy Outcomes of Magmaris, Novel Magnesium Bioresorbable Vascular Scaffolds in Diabetes Mellitus Patients with Acute Coronary Syndrome.
    Włodarczak A; Łanocha M; Szudrowicz M; Barycki M; Gosiewska A; Kulczycki JJ; Lesiak M; Doroszko A; Rola P
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Differences in the Clinical Features and Outcomes of Patients with Acute Coronary Syndrome Treated with Two Generations (Absorb and Magmaris) of Bioresorbable Vascular Scaffolds.
    Włodarczak A; Rola P; Szudrowicz M; Łanocha M; Barycki M; Kulczycki JJ; Gosiewska A; Turkiewicz K; Lesiak M; Doroszko A
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early outcome of magnesium bioresorbable scaffold implantation in acute coronary syndrome-the initial report from the Magmaris-ACS registry.
    Wlodarczak A; Lanocha M; Jastrzebski A; Pecherzewski M; Szudrowicz M; Jastrzebski W; Nawrot J; Lesiak M
    Catheter Cardiovasc Interv; 2019 Apr; 93(5):E287-E292. PubMed ID: 30537203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid-term safety and efficacy of magnesium bioresorbable vascular scaffolds - magmaris in diabetic population. 2-Years outcome in acute coronary syndrome cohort.
    Włodarczak A; Rola P; Barycki M; Furtan Ł; Łanocha M; Włodarczak S; Szudrowicz M; Kulczycki JJ; Jaroszewska-Pozorska J; Kędzierska M; Giniewicz K; Doroszko A; Lesiak M
    Diab Vasc Dis Res; 2023; 20(4):14791641231188705. PubMed ID: 37439002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnesium bioresorbable scaffold (Magmaris) versus polymer biodegradable ultrathin drug-eluting stent (Ultimaster) in acute coronary syndrome. Mid-term outcomes (2 years).
    Włodarczak A; Rola P; Włodarczak S; Szudrowicz M; Jaroszewska-Pozorska J; Barycki M; Furtan Ł; Kędzierska M; Doroszko A; Lesiak M
    Postepy Kardiol Interwencyjnej; 2024 Mar; 20(1):67-75. PubMed ID: 38616930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents.
    Rola P; Włodarczak A; Barycki M; Szudrowicz M; Łanocha M; Kulczycki JJ; Turkiewicz K; Woźnica K; Lesiak M; Doroszko A
    J Diabetes Res; 2021; 2021():8636050. PubMed ID: 34859105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bioresorbable magnesium scaffold (Magmaris)-State of the art: From basic concept to clinical application.
    Rola P; Włodarczak S; Doroszko A; Lesiak M; Włodarczak A
    Catheter Cardiovasc Interv; 2022 Nov; 100(6):1051-1058. PubMed ID: 36229949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent.
    Barkholt TØ; Webber B; Holm NR; Ormiston JA
    Catheter Cardiovasc Interv; 2020 Dec; 96(7):E674-E682. PubMed ID: 31710149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population-12-Month Clinical Outcome.
    Rola P; Włodarczak A; Włodarczak S; Barycki M; Szudrowicz M; Łanocha M; Furtan Ł; Woźnica K; Kulczycki JJ; Jaroszewska-Pozorska J; Kędzierska M; Doroszko A; Lesiak M
    J Interv Cardiol; 2022; 2022():5223317. PubMed ID: 36605917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial.
    Byrne RA; Alfonso F; Schneider S; Maeng M; Wiebe J; Kretov E; Bradaric C; Rai H; Cuesta J; Rivero F; Hoppmann P; Schlichtenmaier J; Christiansen EH; Cassese S; Joner M; Schunkert H; Laugwitz KL; Kastrati A
    Eur Heart J; 2019 Jan; 40(2):167-176. PubMed ID: 30520980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives.
    Rapetto C; Leoncini M
    J Thorac Dis; 2017 Aug; 9(Suppl 9):S903-S913. PubMed ID: 28894596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnesium versus poly-L-lactic acid bioresorbable scaffolds: in vivo optical coherence tomography comparison of mechanical performance.
    Abellás-Sequeiros RA; Ocaranza-Sanchez R; Galvaõ-Braga C; Marques J; Gonzalez-Juanatey C
    Arch Cardiol Mex; 2020; 90(1):8-15. PubMed ID: 31996867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German-Austrian ABSORB RegIstRy (GABI-R).
    Nef H; Wiebe J; Achenbach S; Münzel T; Naber C; Richardt G; Mehilli J; Wöhrle J; Neumann T; Biermann J; Zahn R; Kastner J; Schmermund A; Pfannebecker T; Schneider S; Limbourg T; Hamm CW
    Cardiovasc Revasc Med; 2016; 17(1):34-7. PubMed ID: 26431767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: the PRAGUE-22 Study.
    Toušek P; Lazarák T; Varvařovský I; Nováčková M; Neuberg M; Kočka V
    Cardiovasc Drugs Ther; 2022 Dec; 36(6):1129-1136. PubMed ID: 34505954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions).
    Azzalini L; Giustino G; Ojeda S; Serra A; La Manna A; Ly HQ; Bellini B; Benincasa S; Chavarría J; Gheorghe LL; Longo G; Miccichè E; D'Agosta G; Picard F; Pan M; Tamburino C; Latib A; Carlino M; Chieffo A; Colombo A
    Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27765802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.